Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9206 Irinotecan Camptosar 20 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs No 1996 Jan 1, 1998 In Use
J9255 Methotrexate (Accord) Methotrexate 50mg Chemotherapy Antimetabolite Folic Acid Analog No 2014 Dec 7, 2023 In Use
J9322 Pemetrexed (Bluepoint) Pemetrexed (Bluepoint) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Jul 11, 2023 In Use
J2860 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jan 1, 2016 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
J9017 Arsenic Trioxide Trisenox 1 mg Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2002 In Use
J9321 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec 7, 2023 In Use
J9261 Nelarabine Arranon 50 mg Chemotherapy Antimetabolite Purine Analog No 2005 Jan 1, 2007 In Use
J9302 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Jan 1, 2011 In Use
C1086 Temozolomide Temodar 5 mg Chemotherapy Alkylating Agent Tetrazine Yes 1999 Jan 1, 2010 In Use
J9024 Atezolizumab, hyaluronidase-tqjs Tecentriq Hybreza 5mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2024 Mar 26, 2025 In Use
J9341 Thiotepa (tepylute) Tepylute 1mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 2025 Jul 9, 2025 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Rylaze 0.1mg Chemotherapy Miscellaneous Agent Enzyme No 2021 Jan 26, 2022 In Use
NA Cyclosporine NeOral 25mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1995 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J9020 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1984 In Use
Q5158 Denosumab-bnht Bomyntra, Conexxence 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
Infigratinib Truseltiq Multiple Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2021 In Use
J0202 Alemtuzumab Lemtrada 1 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan 1, 2016 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
Q0168 Dronabinol Marinol 5 mg Ancillary Therapy Antiemetic CB1/CB2 Yes 1985 Apr 1, 1998 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct 1, 2019 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.